<DOC>
	<DOCNO>NCT00400777</DOCNO>
	<brief_summary>This study design evaluate efficacy safety combination valsartan hydrochlorothiazide amlodipine hypertensive patient previously treat valsartan hydrochlorothiazide remain uncontrolled . A naturalistic approach take compare two different possible way achieve high dosage triple combination , i.e . 160 mg valsartan 25 mg hydrochlorothiazide amlodipine 10 mg .</brief_summary>
	<brief_title>Efficacy Safety Valsartan , Hydrochlorothiazide Amlodipine Combination Therapy Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Male female patient ≥18 year age Patients treat two high blood pressure medication stable dose consider adequate investigator , minimum two month , blood pressure control accord follow criterion : Systolic Blood Pressure ≥140 mmHg and/or Diastolic Blood Pressure ≥90 mmHg low risk patient ( know target organ damage without risk factor present 1 except Type 2 diabetes mellitus risk factor ) ; Systolic Blood Pressure ≥130 and/or Diastolic Blood Pressure ≥85 mmHg medium risk patient ( know target organ damage 2 risk factor except Type 2 diabetes mellitus ) ; Systolic Blood Pressure ≥130 and/or Diastolic Blood Pressure ≥80 mmHg high risk patient ( know target organ damage , and/or Type 2 diabetic patient and/or clinically identifiable cardiovascular disease ) . OR Systolic Blood Pressure ≥160 mmHg and/or Diastolic Blood Pressure ≥100 mmHg Visits 1 2 previously untreated patient Patients previously treat stop medication consider untreated one month without treatment Obs : The target organ : Brain , Heart , Kidney , Retina . The risk factor : Smoking , Dyslipidemia , Age &gt; 60 year old , Family history cardiovascular disease ( woman &lt; 65 year old men &lt; 55 year old Systolic Blood Pressure ≥180 mmHg and/or Diastolic Blood Pressure ≥110 mmHg Visit 1 Visit 2 Evidence secondary form hypertension , include coarctation aorta , primary hyperaldosteronism , renal artery stenosis , pheochromocytoma Known KeithWagener grade III IV hypertensive retinopathy History hypertensive encephalopathy Cerebrovascular accident myocardial infarction 12 month prior Visit 1 History transient ischemic attack 12 month prior Visit 1 Percutaneous coronary intervention coronary artery bypass graft surgery 12 month prior Visit 1 Diabetes mellitus type 1 Diabetes mellitus type 2 insulin treatment Poorly control type 2 diabetes mellitus History heart failure Grade II IV accord NYHA classification Second third degree heart block without pacemaker Concomitant unstable angina pectoris Concomitant potentially life threaten arrhythmia symptomatic arrhythmia Clinically significant valvular heart disease Women childbearing potential Pregnant nursing ( lactate ) woman Any surgical medical condition , discretion investigator , place patient high risk his/her participation study , likely prevent patient comply requirement study complete trial period Additional protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Valsartan</keyword>
	<keyword>hydrochlorothiazide</keyword>
	<keyword>amlodipine</keyword>
	<keyword>hypertension</keyword>
	<keyword>high blood pressure</keyword>
</DOC>